In CLL patients, proactive and reactive infection management is a major emphasis of treatment. Infections associated with conventional chemotherapy, monoclonal antibody immunochemotherapy, target treatments using B-cell receptor pathway inhibitors, and Bcl-2 antagonists must be addressed and treated promptly. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.